The Clinical Significance Of Pentraxin3in Patients With Coronary Heart Disease And Hypertension

Background and ObjectivesCardiovascular disease based on atherosclerotic lesions is one of the key factorswhich are a serious threat to human health and death in today’s society. Numerousstudies show that the incidence of atherosclerosis is mainly "inflammatoryhypothesis" mechanism, inflammation of blood vessels is an important part in theoccurrence and development of atherosclerotic plaque, and it has a close relationshipbetween the two. Inflammation medium plays an important role at the beginning ofatherosclerotic plaque and in the development and the rupture of plaque. While therelationship between inflammation and hypertension has received increasing attentionin recent years,the endothelial dysfunction and the abnormal levels of rennin-angiotensin-aldosterone-system of hypertension proved closely related toinflammation. High-sensitivity C-reactive protein (hs-CRP) is an acute-phase bloodcirculation reflects the acute inflammatory response reactants, and is an independentrisk factor for cardiovascular events. Pentraxin3(PTX3) was found in recent years,itwas a new family member with hs-CRP in the inflammatory response related markersand can be expressed in atherosclerosis plaques. Its distribution, gene structure,signals induced pathways were different from hs-CRP. By analyzing the PTX3levelsof patients with coronary heart disease and hypertension in Cardiology Department of the First Affiliated Hospital of Zhengzhou University, to explore the relationshipbetween PTX3and CHD and hypertension and discuss the differences of PTX3levelsand clinical significance in patients with coronary heart disease and coronary heartdisease and hypertension.Objects and MethodsObjects From October2012to June2013, Continuous included398patients from thedepartment of cardiology of the First Affiliated Hospital of Zhengzhou University.Methods Patients who met the inclusion criteria were enrolled and registeredconsecutively, the researchers recorded the baseline clinical characteristics in thestandard Case Report Form (CRF).1. Written consent: All the patients or their relatives signed the written consent andwere informed of the benefits of parpicipating this trial, they can withdrawl thisstudy at any time of the study.2. Record baseline data: including basic patient information (demographiccharacteristics, contact information), past history (risk factors, history ofcardiovascular and other diseases, etc.), personal history, laboratory tests(including blood lipids, coagulation,Hcy, CRP, PTX3, cTnI, etc.) and otherinformation.3. Transmission machines and statistical analysis: The results obtained usingSPSS17.0statistical software to analysis, measurement results of quantitative datawere expressed as mean±standard deviation (mean±SD),qualitative data byfrequency (percentage,%), quantitative and qualitative information userespectively independent samples t test and chi-square test; PTX3levels remainslogarithm normal distribution, using t test, P <0.05was considered statisticallymeaningful. Using Pearson correlation test was used for correlation analysis, P<0.05indicates a significant difference. Results1.398patients from the department of cardiology of the First Affiliated Hospitalof Zhengzhou University， excluded patients249cases (62.56%), theremaining149cases met the study criteria were selected;98positive cases ofcoronary angiography,54males and44females, average age56.4±8.4yearsold, of which46cases with hypertension (group A),26males and20females,average age56.1±7.5years old,52cases without hypertension (group B),28males and24females, average age56.6±8.0years old, of which coronaryangiography of coronary stenosis less than50%, and clinical symptomsexclude coronary heart disease and hypertension,51cases the control group(group C),25males and26females, average age (55.4±7.2) years old.2. The gender, age, body mass index, smoking history, drinking history, platelet,HDL-C, ALB, BUN, Scr and fasting blood glucose have no obviousdifference between group A, group B and group C (P>0.05); the LDL-C,TG, TC, cTnI, hs-CRP levels of group A and group B is higher than groupc,the difference was statistically significant (P <0.05). the LDL-C, TG, TC,cTnI, hs-CRP levels indicators no significant difference between group A andgroup B (P>0.05).3. Pentraxin3(PTX3) level after taking logarithm remains normal distribution,the pentraxin3(PTX3) level of coronary heart disease(CHD) along withhypertension group (group A) is over than the control group (group C)(P<0.05); the pentraxin3(PTX3) level of coronary heart disease(CHD) group(group B) is over than the control group (group C)(P <0.05); the pentraxin3(PTX3) level of(group A is over than group B (P <0.05); the difference wasstatistically significant.4. Pearson correlation analysis showed: PTX3levels with LDL-C (r=0.136, P=0.014) and cTnI (r=0.249, P=0.004) were positively correlated; PTX3levelsand HDL-C (r=-0.184, P=0.032) were negatively correlated. Gensiniscore had no significant correlation with PTX3; Gensini score with hs-CRP (r=0.239, P=0.018) and cTnI (r=0.274, P=0.013) were positively correlated.Conclusions1. Pentraxin3levels were elevated in patients with coronary heart disease, and werefurther increased for patients with hypertension.2. There was no significant correlation between PTX3levels and the severity ofcoronary stenosis.